Core Insights - Repare Therapeutics (RPTX) shares increased by 8% following the announcement of dosing the first patient in an early-stage study for the combination of RP-3467 and AstraZeneca's Lynparza to treat advanced solid tumors [1] - The combination of RP-3467 and Lynparza has shown promising preclinical results, leading to complete and durable tumor regressions without additional toxicities, indicating potential to improve patient outcomes by addressing PARP inhibitor resistance [2] - The ongoing phase I POLAR study aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, targeting 52 patients with specific advanced solid tumors [3][4] Company Pipeline - Repare utilizes its CRISPR-enabled SNIPRx platform to develop targeted cancer therapies focusing on genomic instability and DNA damage repair [5] - The company is also evaluating lunresertib, a PKMYT1 inhibitor, in combination with camonsertib, an ATR inhibitor, in a phase I study for ovarian and endometrial cancer, with top-line data expected soon [6] - RP-1664, an oral PLK4 inhibitor, is currently in a phase I study for advanced solid tumors, indicating a diverse clinical-stage pipeline [7] Market Context - Year to date, RPTX shares have decreased by 53.6%, contrasting with a 2% decline in the broader industry [3] - Repare currently holds a Zacks Rank 3 (Hold), while ANI Pharmaceuticals and Alnylam Pharmaceuticals are ranked 1 (Strong Buy) [8]

Core Viewpoint - Repare Therapeutics is approaching a significant milestone with the upcoming results from its phase 1 MYTHIC trial, which is testing the combination of lunresertib and camonsertib for treating platinum-resistant ovarian and endometrial cancers. The data expected in Q4 2024 will be crucial in determining the viability of its SNIPRx platform for developing Synthetic Lethality drugs [2][3]. Company Overview - Repare Therapeutics is focused on developing lunresertib in combination with camonsertib for patients with specific genetic mutations in platinum-resistant ovarian and endometrial cancers. The MYTHIC trial is currently ongoing to evaluate this combination [3]. - The global ovarian cancer market is projected to reach $11.18 billion by 2029, indicating a substantial market opportunity for effective treatments targeting this disease [3]. Clinical Trials and Data - The MYTHIC trial aims to assess the efficacy of lunresertib and camonsertib in a patient population with genetic alterations. Data from 20 to 30 patients is expected to be released in Q4 2024 [3]. - Preliminary results from a cohort of 26 pre-treated gynecologic cancer patients showed an objective response rate of 38.5% and a clinical benefit rate of 57.7% when treated with lunresertib and camonsertib [3]. Financials - As of June 30, 2024, Repare Therapeutics reported cash, cash equivalents, and marketable securities totaling $208.1 million. The company anticipates its cash runway to extend into the second half of 2026 due to a strategic reprioritization of its pipeline and a reduction in workforce by 25% [4][5]. Strategic Focus - The company is narrowing its pipeline to focus on lunresertib, camonsertib, RP-1664, and RP-3467, while reducing preclinical research and discovery activities. This strategic shift is expected to yield annual savings of $15 million [5]. Future Catalysts - The next significant catalyst for Repare Therapeutics will be the data release from the MYTHIC trial in Q4 2024. If the results are positive, it could lead to the initiation of a phase 3 study in 2025 targeting patients with genomic alterations [7]. - Additionally, the company is exploring other opportunities, including a monotherapy program for camonsertib in non-small cell lung cancer, with initial results expected in 2025 [7].

Repare Therapeutics Inc. (RPTX) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.53%. A quarter ago, it was expected that this company would post a loss of $0.10 per share when it actually produced earnings of $0.30, delivering a surprise of 400%. Over the last four quarters, the company ha ...

ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%. In the past 30 days, the Zacks Consensus Estimate for Compugen's 2024 earnings per share has increased from 2 cents to 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have gained 5.6%. CGEN's earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%. In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) Québec Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) St-Laurent, Québec, Canada H4S 1Z9 (Address of principal executive offices) (Zip Co ...

Exhibit 99.1 Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results Phase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with RP2D First patient dosed in Phase 1 MYTHIC clinical trial of lunresertib in combination with the WEE1 inhibitor, Debio 0123; first clinical trial inhibiting both PKMYT1 and WEE1 Initiating P ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39335 Repare Therapeutics Inc. (Exact name of Registrant as specified in its Charter) Québec Not applicable (State or other jurisdict ...

• Lunresertib • Presented initial positive data from its ongoing Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) alone and in combination with camonsertib in patients with advanced solid tumors harboring CCNE1 amplification or FBXW7 or PPP2R1A deleterious alterations at the 2023 American Association for Cancer Research (AACR)-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Initial combination data included an overall RECIST response rate of 50% in ten patients with hea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-39335 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) ( ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR Commission File Number: 001-39335 Repare Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) (State ...